Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 26 clinical trials
Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis

Phase I / II randomized, single-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of melatonin administration combined with ocrelizumab in patients with Progressive

immunosuppressive agents
ocrelizumab
antioxidants
melatonin
  • 3 views
  • 21 Jul, 2022
  • 3 locations
Ocrelizuamb for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease. (CELLO)

criteria for DIS) will be randomized 1:1 to receive ocrelizumab treatment or placebo (standard of care).

ocrelizumab
disease or disorder
  • 3 views
  • 29 May, 2022
  • 1 location
COVID-19 Booster Vaccination in Persons With Multiple Sclerosis

The success of the U.S. vaccination program against SARS-Cov-2 is shown by a dramatic drop in infection rates, hospitalizations and deaths.However, it appears that many persons who take medications that chronically suppress the immune system do not produce neutralizing antibodies to COVID-19 proteins in response to vaccination. This group includes …

Accepts healthy volunteers
  • 0 views
  • 22 Mar, 2022
  • 1 location
Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies

Vaccination coverage against HBV in France is around 30% in the adult population. Treatment with anti-CD20 is associated with a risk of reactivation of hepatitis B or acute or fulminant hepatitis in first-infected patients. HBV vaccination is recommended as before any anti-CD20 treatment in unimmunized patients. However, there is no …

  • 0 views
  • 12 Feb, 2021
  • 1 location
Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

The investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures with

  • 0 views
  • 14 Jun, 2022
  • 1 location
COVID Vaccine Response in MS

The primary goal of this study is to assess the impact of the two major disease modifying therapy (DMT) classes (B cell therapies and S1P modulators) on humoral and cell-mediated immunity to SARS- CoV-2 vaccination compared to non-MS controls. We have chosen to compare DMT-treated MS patients to non-MS controls …

Accepts healthy volunteers
ocrelizumab
gilenya
fingolimod
disease or disorder
  • 0 views
  • 07 Oct, 2021